Cargando…
Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study
BACKGROUND: The effectiveness and safety of initiating sacubitril/valsartan therapy among patients who are hospitalized for acute heart failure (HF) is unclear. METHODS: A cohort of 3736 patients with HF with reduced ejection fraction (HFrEF) hospitalized for acute HF was identified from Chang Gung...
Autores principales: | Chen, Dong-Yi, Chen, Chun-Chi, Tseng, Chi-Nan, Chen, Shao-Wei, Chang, Shang-Hung, Huang, Wen-Kuan, Wen, Ming-Shien, Hsieh, Ming-Jer, Hsieh, I-Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515399/ https://www.ncbi.nlm.nih.gov/pubmed/34693232 http://dx.doi.org/10.1016/j.eclinm.2021.101149 |
Ejemplares similares
-
Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hsieh, Hui-Ling, et al.
Publicado: (2021) -
Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
por: Chang, Po‐Cheng, et al.
Publicado: (2020) -
Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021) -
Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril–valsartan
por: Yang, Tsun-Yu, et al.
Publicado: (2022) -
Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
por: Niu, Chih‐Yuan, et al.
Publicado: (2022)